At Nivien, we are driven to help people with cancer and other diseases live longer, healthier lives.
We are a startup from the IndieBio Accelerator and Harvard Innovation Labs with a therapeutic strategy based on novel biology from Harvard Medical School.
Our molecules harness the potential of the Hippo-YAP signaling pathway to treat cancer and other indications where Hippo plays an important role. We have patented the first inhibitors of the LATS1/2 kinases and are currently in preclinical testing for several cancers.
Defeating mechanisms that resistant, difficult-to-treat cancers use to evade drug-induced cell death
Overcoming irreversible tissue damage such as fibrosis to promote healthier, better-functioning organs
Increasing cell proliferation to improve cardiac function after myocardial infarction
Read more about Nivien in Forbes:
© 2017 — Nivien Therapeutics Company